ARS Pharmaceuticals to Host Q3 Results Call November 5
The biopharmaceutical company will hold a conference call and webcast to review its third quarter 2026 financial performance.
Updated on Oct. 28, 2026 in Asthma
ARS Pharmaceuticals, based in San Diego, is scheduled to host a conference call and webcast to review its third quarter 2026 financial results on November 5, 2026. The company currently markets neffy, an epinephrine nasal spray, in multiple regions.
Why it matters
The company's quarterly financial disclosures provide transparency into its current business operations and the development of its product pipeline, including new treatments currently undergoing clinical evaluation.
The firm markets its epinephrine nasal spray for patients with a minimum weight of 33 lbs. (15kg). Following the scheduled event, a recording of the company webcast will remain available for public viewing for 30 days.
The players
ARS Pharmaceuticals
This biopharmaceutical company specializes in developing needle-free delivery systems for drugs including epinephrine for severe allergic reactions.
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs and medical devices.
European Medicines Agency
This agency of the European Union is responsible for the scientific evaluation, supervision, and safety monitoring of medicines developed for human and veterinary use.
The details
ARS Pharmaceuticals received approval from the FDA and European Medicines Agency for its epinephrine spray, marketed as neffy in the U.S. and Europe, and as 优敏速 in China. Additionally, the company is testing ARS-2, a candidate for chronic spontaneous urticaria currently in a Phase 2b clinical trial.
Timeline
October 28, 2026: The company announced the upcoming financial results conference call.
November 5, 2026: The company will host the Q3 2026 financial results call.
Health Landscape
The company's R&D strategy reflects a broader trend of shifting from traditional needle-based delivery to nasal formulations for common medical conditions. This update on the Phase 2b clinical trial of ARS-2 highlights the evolving scope of the company's research pipeline.
While the conference call provides financial data for investors, the focus on neffy delivery mechanisms impacts patients needing rapid epinephrine access. Those interested in the technology's availability can monitor the company website for updates on product distribution and pipeline progress.
The takeaway
Interested participants should ensure they register in advance to access the dial-in details for the November 5 call. All interested parties can also access the presentation slides directly through the company's online investor portal.
Further reading
For more information on current treatment trends, visit the Asthma section.
More information
For more information, visit the ARS Pharmaceuticals company website.
